GLYCOT THERAPEUTICS LLC — Department of Health and Human Services SBIR Phase I: 300

Description

Project Summary Abstract The goal of this proposal is to establish a robust and scalable process for production of specially engineered glycoforms of intravenous immunoglobulin IVIG with markedly enhanced anti inflammatory activity We propose to achieve this goal by exploiting a chemoenzymatic glycosylation remodeling technology IVIG is a mixture of antibodies prepared from the pooled sera of thousands of healthy donors It has been widely used for the treatment of autoimmune disease and chronic inflammation such as rheumatoid arthritis RA with multi billion dollar annual sales globally Although IVIG treatment is efficacious in a number of indications current IVIG preparations have distinct limitations including variable efficacy the need of unusually high doses shortage of supplies potential contaminations and side effects As a result alternatives for IVIG with more potent therapeutic efficacy thus much lower doses more consistent in components and minimal side effects are highly desired Recent studies in animal models have suggested that the sialylated Fc glycoform of IVIG could be the major active form that confers the anti inflammatory activities It has been demonstrated that the enrichment of the Fc sialylation glycoforms could achieve full activity of IVIG in several mouse models of autoimmune disease with less than of the doses of commercial IVIG In addition other studies demonstrate that the glycosylation sialylation of Fab glycan may also play a role in anti inflammatory activities Therefore modification of IVIG with full sialylation at both Fc and Fab domain points to a very promising approach to improving the therapeutic efficacy with more homogeneous components Attempts to perform sequential galactosylation and sialylation of IVIG to obtain fully sialylated IVIG resulted in only partial success due to the tremendous heterogeneity of the original glycoforms of IVIG the relatively low efficiency of enzymatic sialylation and side reactions In addition the global sequential addition of monosaccharides could not achieve selective glycan transformation at either Fc or Fab domains On the other hand recombinant antibodies from mammalian cell lines has been hitherto difficult to produce fully sialylated Fc glycoforms To meet with this challenge Prof Lai Xi Wang s laboratory has developed a chemoenzymatic platform technology that permits specific glycoengineering of heterogeneous antibodies to provide structurally well defined homogeneous glycoforms In particular making use of the substrate specificity of a handful glycosynthases the technology was capable of distinguishably engineering the Fab and Fc glycans as demonstrated by the glycosylation remodeling of cetuximab This technology development has resulted in US patent applications three have been issued and five are pending To further develop and apply this platform technology GlycoT Therapeutics a startup was recently founded focusing on exploring the chemoenzymatic technology for improving protein therapeutics In this SBIR grant application we propose to apply the chemoenzymatic technology for glycan remodeling of IVIG aiming to improve its anti inflammatory efficacy We will achieve the goal by performing three specific aims Aim Establish a scalable chemoenzymatic process for production of fully sialylated intravenous immunoglobulin IVIG on a relatively large scale Aim Perform site specific glycoengineering of IVIG at the Fc and Fab domains for evaluating the contributions of Fab and Fc glycosylations to anti inflammatory activity Aim Evaluate anti inflammatory activity of various glycoforms of IVIG in mouse inflammation models This Phase I studies will pave a way to produce sufficient amount of well defined Fc and Fab glycoforms of IVIG for expected Phase II evaluation for extensive preclinical studiesls Project Narrative The goal of this proposal is to establish a robust and scalable process for production of specially engineered glycoforms of intravenous immunoglobulin IVIG with markedly enhanced anti inflammatory activity